View ValuationSurgical Science Sweden 将来の成長Future 基準チェック /36Surgical Science Sweden利益と収益がそれぞれ年間28.8%と10.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に4.2% 28.8%なると予測されています。主要情報28.8%収益成長率28.84%EPS成長率Medical Equipment 収益成長16.5%収益成長率10.3%将来の株主資本利益率4.16%アナリストカバレッジLow最終更新日24 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Oct 01Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026.お知らせ • Sep 04+ 3 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2026 Results on Aug 19, 2026Surgical Science Sweden AB (publ) announced that they will report first half, 2026 results on Aug 19, 2026お知らせ • May 16Surgical Science Sweden AB (Publ) Appoints Gisli Hennermark as New Chairman of the Board of DirectorsSurgical Science Sweden AB (publ) announced at its AGM held on May 15, 2025, the shareholders approved Gisli Hennermark was elected new Chairman of the Board of Directors.お知らせ • Feb 04Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025. Location: gothenburg Swedenお知らせ • Dec 20Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million.Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million on December 19, 2024. A cash consideration valued at £0.13 per share will be paid by Surgical Science Sweden AB (publ) on a cash and debt free basis. The consideration necessary to satisfy the Acquisition in full will be funded from Surgical Science's existing cash resources. Surgical Science drew down £17 million under the DB Facility prior to the date of this announcement and intends to settle the consideration payable pursuant to the Acquisition out of the cash on its balance sheet, including the funds drawn down under the DB Facility. Strand Hanson, joint financial adviser to Surgical Science, confirms that it is satisfied that sufficient resources are available to Surgical Science to satisfy in full the cash consideration payable to Intelligent Ultrasound Shareholders under the terms of the Acquisition. Surgical Science does not intend to make any material changes to the balance of skills and functions of the employees and management of Intelligent Ultrasound. Surgical Science will fully safeguard the existing employment rights, including pension rights, of Intelligent Ultrasound's employees. The Intelligent Ultrasound Directors intend to recommend unanimously that Intelligent Ultrasound Shareholders vote in favour of the Scheme at the Court Meeting and vote in favour of the Resolution to be proposed at the General Meeting as the Intelligent Ultrasound Directors. It is intended that the Acquisition will be implemented by way of a Court-sanctioned Scheme of Arrangement. The Intelligent Ultrasound Directors, who have been so advised by Cavendish as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. The approval of the Scheme by a majority in number of the Intelligent Ultrasound Shareholders who are present and vote (and are entitled to vote), whether in person or by proxy, at the Court Meeting and who represent 75% or more in value of the Scheme Shares voted by such Intelligent Ultrasound Shareholders, he Resolution required to approve and implement the Scheme being duly passed by Intelligent Ultrasound Shareholders representing the requisite majority or majorities of the votes cast at the General Meeting and third party clearance. It is intended that the London Stock Exchange will be requested to cancel admission of the Intelligent Ultrasound Shares to trading on AIM to become effectiveas soon as practicable after the Effective Date. The Scheme is expected to become effective in the first quarter of 2025, provided all the conditions are satisfied. Pareto Securities AB, Strand Hanson Limited, Baker McKenzie LLP acted as advisor to Surgical Science, Cavendish Capital Markets RBG Legal Services Limited, trading as Memery Crystal, is acting as advisers to Intelligent Ultrasound.お知らせ • Oct 29+ 2 more updatesSurgical Science Sweden AB (publ) to Report Nine Months, 2025 Results on Nov 13, 2025Surgical Science Sweden AB (publ) announced that they will report nine months, 2025 results on Nov 13, 2025お知らせ • Oct 22Surgical Science Sweden AB (publ) Appoints Nomination Committee for the 2025 Annual General MeetingSurgical Science Sweden AB (publ) appointed following members to the nomination Committee for the 2025 Annual General Meeting: Åsa Hedin, appointed by Marknads potential AB Anna Sundberg, appointed by Handelsbanken Fonder, Erik Sprinchorn, appointed by TIN Fonder, Roland Bengtsson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company’s Nomination Committee established at the Annual General Meeting of Surgical Science on May 16, 2024. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just below 27 percent of all shares in the company as of August 31, 2024. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding: (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee, (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.お知らせ • Jul 01Surgical Science Sweden AB (publ) Appoints Tom Englund as New CEO, Effective October 1, 2024Surgical Science Sweden AB (publ) announced that Tom Englund will take over as the new CEO of Surgical Science on October 1, 2024. Tom currently works as COO and Deputy CEO at Instabee. He will succeed the current CEO Gisli Hennermark, who after October 1 will remain in an advisory role until the end of March 2025. Tom Englund holds a Master of Science in Industrial Engineering and Management from Linköping University. Previous experiences include Accenture and Roland Berger, various roles within Atlas Copco where Tom spent seven years based in Stockholm and Shanghai, and Tobii where he worked for twelve years. At Tobii, a leading company in eye tracking, revenues during Tom's tenure grew from around SEK 200 million to SEK 1.4 billion. Tom was CEO of the Tobii Pro business unit and later also Deputy CEO of the Tobii Group. Since 2021, Tom has worked for Instabox, whichthrough a merger with Budbee in 2022 became Instabee. Tom is the COO and Deputy CEO at Instabee. From his roles, Tom has experience in leading fast-growing high-tech organizations with a focus on profitable growth, developing business models, acquiring and integrating businesses, and scaling and merging organizations in a complex structure and international environment. Tom will start his employment in Surgical Science on August 19 and will assume the position of CEO on October 1, 2024. Tom has no board assignments except for internal assignments within the Instabee Group.お知らせ • Mar 12Gisli Hennermark Intends to Leave as CEO of Surgical Science Sweden AB (Publ)Surgical Science Sweden AB (publ) announced that Gisli Hennermark, CEO has informed the board that he intends to leave his position. The board now initiates the work of finding a successor to Gisli. That process will be led by the chairman of the board, Roland Bengtsson. Gisli remains as CEO until the board appoints a new CEO and will be an advisor to the new CEO until March, 2025.お知らせ • Nov 10+ 2 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2024 Results on Aug 22, 2024Surgical Science Sweden AB (publ) announced that they will report first half, 2024 results on Aug 22, 2024お知らせ • Oct 26Surgical Science Sweden AB (publ) Announces Appointments to its Nomination CommitteeSurgical Science Sweden AB (publ) announced that the following were appointed to it's Nomination Committee for the 2024 Annual General Meeting: Åsa Hedin, appointed by Marknadspotential AB; Celia Grip, appointed by Swedbank Robur Fonder; Anna Sundberg, appointed by Handelsbanken Fonder; Roland Bengtsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company's Nomination Committee established at the Annual General Meeting of Surgical Science on May 6, 2020. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just above 27% of all shares in the company as of September 30, 2023. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable), (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.お知らせ • Oct 24Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024. Agenda: To consider the election of board members; to consider the election of Chairman of the Board; to consider the resolution on board remuneration with the division between the chairman and other members of the board; to consider the resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable); to consider the election of auditors; to consider the resolution on remuneration of auditors; and to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.お知らせ • Aug 27Surgical Science Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024Surgical Science Sweden AB (publ) announced that they will report fiscal year 2023 results on Feb 21, 2024お知らせ • May 18Surgical Science Sweden AB (publ) Approves Election of Åsa Bredin as Board MemberSurgical Science Sweden AB (publ) at its Annual General Meeting held on May 17, 2023, approved new election of Åsa Bredin as Board member.業績と収益の成長予測OTCPK:SUSR.F - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,230168171215412/31/20271,104135132169412/31/20269889411714243/31/20269775293150N/A12/31/2025992673080N/A9/30/2025975701764N/A6/30/2025943924290N/A3/31/202594714156104N/A12/31/202488413290137N/A9/30/202486019373120N/A6/30/2024838198100151N/A3/31/2024842208159206N/A12/31/2023883234194238N/A9/30/2023906253231277N/A6/30/2023901234194234N/A3/31/2023872221140179N/A12/31/202280318895129N/A9/30/20227501381138N/A6/30/20226401246180N/A3/31/20224891014559N/A12/31/2021367862539N/A9/30/2021209305969N/A6/30/2021138211726N/A3/31/2021122181120N/A12/31/2020105161523N/A9/30/202010414414N/A6/30/2020112194254N/A3/31/2020107173747N/A12/31/201910213N/A55N/A9/30/2019886N/A56N/A6/30/201970-5N/A12N/A3/31/201968-5N/A9N/A12/31/201866-5N/A7N/A9/30/201860-3N/A9N/A6/30/201857-6N/A0N/A3/31/201856-7N/A8N/A12/31/201757-3N/A7N/A9/30/2017654N/A6N/A6/30/2017603N/A12N/A3/31/2017594N/A11N/A12/31/2016583N/A13N/A12/31/2015522N/A8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SUSR.Fの予測収益成長率 (年間28.8% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: SUSR.Fの収益 ( 28.8% ) はUS市場 ( 16.7% ) よりも速いペースで成長すると予測されています。高成長収益: SUSR.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: SUSR.Fの収益 ( 10.3% ) US市場 ( 12.4% ) よりも低い成長が予測されています。高い収益成長: SUSR.Fの収益 ( 10.3% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SUSR.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 4.2 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 21:14終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Surgical Science Sweden AB (publ) 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Simon JonssonBerenbergSimon LarssonDanske BankKristofer Liljeberg-SvenssonDNB Carnegie3 その他のアナリストを表示
お知らせ • Oct 01Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026Surgical Science Sweden AB (publ), Annual General Meeting, May 21, 2026.
お知らせ • Sep 04+ 3 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2026 Results on Aug 19, 2026Surgical Science Sweden AB (publ) announced that they will report first half, 2026 results on Aug 19, 2026
お知らせ • May 16Surgical Science Sweden AB (Publ) Appoints Gisli Hennermark as New Chairman of the Board of DirectorsSurgical Science Sweden AB (publ) announced at its AGM held on May 15, 2025, the shareholders approved Gisli Hennermark was elected new Chairman of the Board of Directors.
お知らせ • Feb 04Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025Surgical Science Sweden AB (publ), Annual General Meeting, May 15, 2025. Location: gothenburg Sweden
お知らせ • Dec 20Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million.Surgical Science Sweden AB (publ) (OM:SUS) reached agreement to acquire Intelligent Ultrasound Group plc (AIM:IUG) from group of sellers for £42.5 million on December 19, 2024. A cash consideration valued at £0.13 per share will be paid by Surgical Science Sweden AB (publ) on a cash and debt free basis. The consideration necessary to satisfy the Acquisition in full will be funded from Surgical Science's existing cash resources. Surgical Science drew down £17 million under the DB Facility prior to the date of this announcement and intends to settle the consideration payable pursuant to the Acquisition out of the cash on its balance sheet, including the funds drawn down under the DB Facility. Strand Hanson, joint financial adviser to Surgical Science, confirms that it is satisfied that sufficient resources are available to Surgical Science to satisfy in full the cash consideration payable to Intelligent Ultrasound Shareholders under the terms of the Acquisition. Surgical Science does not intend to make any material changes to the balance of skills and functions of the employees and management of Intelligent Ultrasound. Surgical Science will fully safeguard the existing employment rights, including pension rights, of Intelligent Ultrasound's employees. The Intelligent Ultrasound Directors intend to recommend unanimously that Intelligent Ultrasound Shareholders vote in favour of the Scheme at the Court Meeting and vote in favour of the Resolution to be proposed at the General Meeting as the Intelligent Ultrasound Directors. It is intended that the Acquisition will be implemented by way of a Court-sanctioned Scheme of Arrangement. The Intelligent Ultrasound Directors, who have been so advised by Cavendish as to the financial terms of the Acquisition, consider the terms of the Acquisition to be fair and reasonable. The approval of the Scheme by a majority in number of the Intelligent Ultrasound Shareholders who are present and vote (and are entitled to vote), whether in person or by proxy, at the Court Meeting and who represent 75% or more in value of the Scheme Shares voted by such Intelligent Ultrasound Shareholders, he Resolution required to approve and implement the Scheme being duly passed by Intelligent Ultrasound Shareholders representing the requisite majority or majorities of the votes cast at the General Meeting and third party clearance. It is intended that the London Stock Exchange will be requested to cancel admission of the Intelligent Ultrasound Shares to trading on AIM to become effectiveas soon as practicable after the Effective Date. The Scheme is expected to become effective in the first quarter of 2025, provided all the conditions are satisfied. Pareto Securities AB, Strand Hanson Limited, Baker McKenzie LLP acted as advisor to Surgical Science, Cavendish Capital Markets RBG Legal Services Limited, trading as Memery Crystal, is acting as advisers to Intelligent Ultrasound.
お知らせ • Oct 29+ 2 more updatesSurgical Science Sweden AB (publ) to Report Nine Months, 2025 Results on Nov 13, 2025Surgical Science Sweden AB (publ) announced that they will report nine months, 2025 results on Nov 13, 2025
お知らせ • Oct 22Surgical Science Sweden AB (publ) Appoints Nomination Committee for the 2025 Annual General MeetingSurgical Science Sweden AB (publ) appointed following members to the nomination Committee for the 2025 Annual General Meeting: Åsa Hedin, appointed by Marknads potential AB Anna Sundberg, appointed by Handelsbanken Fonder, Erik Sprinchorn, appointed by TIN Fonder, Roland Bengtsson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company’s Nomination Committee established at the Annual General Meeting of Surgical Science on May 16, 2024. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just below 27 percent of all shares in the company as of August 31, 2024. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding: (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee, (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.
お知らせ • Jul 01Surgical Science Sweden AB (publ) Appoints Tom Englund as New CEO, Effective October 1, 2024Surgical Science Sweden AB (publ) announced that Tom Englund will take over as the new CEO of Surgical Science on October 1, 2024. Tom currently works as COO and Deputy CEO at Instabee. He will succeed the current CEO Gisli Hennermark, who after October 1 will remain in an advisory role until the end of March 2025. Tom Englund holds a Master of Science in Industrial Engineering and Management from Linköping University. Previous experiences include Accenture and Roland Berger, various roles within Atlas Copco where Tom spent seven years based in Stockholm and Shanghai, and Tobii where he worked for twelve years. At Tobii, a leading company in eye tracking, revenues during Tom's tenure grew from around SEK 200 million to SEK 1.4 billion. Tom was CEO of the Tobii Pro business unit and later also Deputy CEO of the Tobii Group. Since 2021, Tom has worked for Instabox, whichthrough a merger with Budbee in 2022 became Instabee. Tom is the COO and Deputy CEO at Instabee. From his roles, Tom has experience in leading fast-growing high-tech organizations with a focus on profitable growth, developing business models, acquiring and integrating businesses, and scaling and merging organizations in a complex structure and international environment. Tom will start his employment in Surgical Science on August 19 and will assume the position of CEO on October 1, 2024. Tom has no board assignments except for internal assignments within the Instabee Group.
お知らせ • Mar 12Gisli Hennermark Intends to Leave as CEO of Surgical Science Sweden AB (Publ)Surgical Science Sweden AB (publ) announced that Gisli Hennermark, CEO has informed the board that he intends to leave his position. The board now initiates the work of finding a successor to Gisli. That process will be led by the chairman of the board, Roland Bengtsson. Gisli remains as CEO until the board appoints a new CEO and will be an advisor to the new CEO until March, 2025.
お知らせ • Nov 10+ 2 more updatesSurgical Science Sweden AB (publ) to Report First Half, 2024 Results on Aug 22, 2024Surgical Science Sweden AB (publ) announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Oct 26Surgical Science Sweden AB (publ) Announces Appointments to its Nomination CommitteeSurgical Science Sweden AB (publ) announced that the following were appointed to it's Nomination Committee for the 2024 Annual General Meeting: Åsa Hedin, appointed by Marknadspotential AB; Celia Grip, appointed by Swedbank Robur Fonder; Anna Sundberg, appointed by Handelsbanken Fonder; Roland Bengtsson, Chairman of the Board. The appointments have been made in accordance with the instructions regarding principles for the appointment of the company's Nomination Committee established at the Annual General Meeting of Surgical Science on May 6, 2020. The shareholders that have appointed the members of the Nomination Committee represented in aggregate just above 27% of all shares in the company as of September 30, 2023. The Nomination Committee shall prepare and submit proposals to the Annual General Meeting regarding (i) election of Chairman of the Meeting, (ii) election of board members, (iii) election of Chairman of the Board, (iv) resolution on board remuneration with the division between the chairman and other members of the board, (v) resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable), (vi) election of auditors, (vii) resolution on remuneration of auditors, and (viii) to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.
お知らせ • Oct 24Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024Surgical Science Sweden AB (publ), Annual General Meeting, May 16, 2024. Agenda: To consider the election of board members; to consider the election of Chairman of the Board; to consider the resolution on board remuneration with the division between the chairman and other members of the board; to consider the resolution on remuneration for the members of the Remuneration and Audit Committee (if applicable); to consider the election of auditors; to consider the resolution on remuneration of auditors; and to the extent deemed necessary, resolution on amendments in current rules for the Nomination Committee.
お知らせ • Aug 27Surgical Science Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 21, 2024Surgical Science Sweden AB (publ) announced that they will report fiscal year 2023 results on Feb 21, 2024
お知らせ • May 18Surgical Science Sweden AB (publ) Approves Election of Åsa Bredin as Board MemberSurgical Science Sweden AB (publ) at its Annual General Meeting held on May 17, 2023, approved new election of Åsa Bredin as Board member.